VANCOUVER, BC–(Marketwired – June 25, 2017) – BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created position, London will have responsibility for leading all external communications, corporate visibility, brand-building, reputation management, financial communications and investor relations.
“The Board of Directors and I are delighted to welcome Catherine London to our senior management team at biOasis. Having worked with Catherine previously, I know she is a forward-thinking communications leader and collaborative relationship builder,” said Dr. Mark Day. “She will play a critical role in the strategic design and execution of communications and investor relations initiatives to drive business growth. I look forward to working with her again.”
“Catherine brings with her the broad pharmaceutical and biotechnology industry expertise and experience we are looking for to help propel biOasis globally,” said Rob Hutchison, founder and chairman of the board of directors. “She will be an instrumental member of the team.”
London has more than 22 years of experience in the pharmaceutical and healthcare industries and has successfully led large, global teams and strategic plans. London most recently served as the head of corporate communications at Purdue Pharma L.P. Prior to Purdue, London served in director-level roles in corporate and product communications at Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. In these roles, her responsibilities included executive, corporate, product and financial communications, government and policy communications and business communications. London has also held senior leadership roles at global consulting firms such as the Chandler Chicco Companies, an inVentiv Health Company, which includes Chamberlain, Chandler Chicco and BioSector2, and at Ruder Finn.
“I believe in Mark’s vision and business strategy for biOasis as well as the promise of the in-house programs and Transcend platform. This is truly an exciting time in the neuroscience field and we have a great story to tell at biOasis,” said London. “I want to thank the board of directors, Rob Hutchison and Mark for this opportunity. I look forward to leading the communications and investor relations on behalf of the company and its shareholders.”
London began her career as a reporter and editor working at print and broadcast outlets in various U.S. markets before taking a turn as a science journal editor and eventually making the transition to public affairs at the American Diabetes Association. London holds a bachelor of arts degree in journalism from Auburn University in Auburn, Ala.
About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company with offices in Canada and the U.S., focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.
Forward-Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors
Dr. Mark Day, President and Chief Executive Officer
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
Company Contact
Graeme Dick
biOasis Technologies Inc.
[email protected]
1- (403) 561-8989
